No association Between Calcium Channel Blockers and Survival in Patients with Cancer: A systematic Review and Meta-analysis

  • Sun, Hong (Department of Clinical Pharmacy, School of Pharmacy) ;
  • Zhuang, Rong-Yuan (Department of Medical Oncology, Zhongshan Hospital, Fudan University) ;
  • Li, Tao (Department of Clinical Pharmacy, School of Pharmacy) ;
  • Zheng, Yuan-Ting (Department of Clinical Pharmacy, School of Pharmacy) ;
  • Cai, Wei-Min (Department of Clinical Pharmacy, School of Pharmacy)
  • 발행 : 2016.08.01


Background: The association between calcium channel blockers (CCBs) and survival in cancer patients remains unclear and the results of related studies are conflicting. The objective of the study was to investigate the association between calcium channel blockers (CCBs) use and survival in cancer patients. Materials and Methods: We searched PubMed, EMBASE, Web of Science and Cochrane Library for studies published before January 2016 with the terms related to CCBs and survival in cancer patients. The information was reviewed and extracted by two evaluators independently. Data of publications was extracted and calculated into hazard ratios (HRs) for overall survival (OS). Statistical analysis was performed by using Review Manager 5.3. Results: There were 11 studies included in our meta-analysis. Analysis of all studies showed that CCBs use was not associated with survival in cancer patients (HR=1.07; 95% CI: 0.91-1.25; P=0.42). No association between CCBs use and overall survival in cancer patients was existed whether in Asian (HR=1.18, 95% CI: 0.72-1.93; P=0.52) or Caucasian population (HR=1.03, 95% CI: 0.89-1.20; P=0.66). Conclusions: There is no evidence that CCBs use is associated with a better or worse outcome of survival in cancer patients.


  1. Belpomme D, Gauthier S, Pujade-Lauraine E, et al (2000). Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol, 11, 1471-6.
  2. Bergman GJ, Khan S, Danielsson B, et al.(2014). Breast cancer risk and use of calcium channel blockers using Swedish population registries. JAMA Intern Med, 174, 1700-1.
  3. Chae YK, Dimou A, Pierce S, et al(2014). The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma, 55, 2822-9.
  4. Choi DL, Jang SJ, Cho S, et al (2014). Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist. Bioorg Med Chem Lett, 24, 1565-70.
  5. Chong VH, Telisinghe PU, Lim E, et al (2016). Cancers among south-east asian nationals in brunei darussalam. Asian Pac J Cancer Prev, 17, 845-9.
  6. Coleman CI, Baker WL, Kluger J, et al (2008). Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens, 26, 622-9.
  7. Fan Y, Zhou Y, Gong D, et al (2015). No evidence for increased prostate cancer risk among calcium channel blockers user. Int J Cardiol, 201, 255-7.
  8. Grimaldi-Bensouda L, Klungel O, Kurz X, et al (2016). Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open, 6, 9147.
  9. Guo DQ, Zhang H, Tan SJ, et al (2014). Nifedipine promotes the proliferation and migration of breast cancer cells. PLoS One, 9, 113649.
  10. Hashim D, Boffetta P, La Vecchia C, et al (2016). The global decrease in cancer mortality: trends and disparities. Ann Oncol, 27, 926-33
  11. He LR, Qiao W, Liao ZX, et al (2015). Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer, 15, 111.
  12. Holmes S, Griffith EJ, Musto G, et al (2013). Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol, 37, 881-5.
  13. Kaddour-Djebbar I, Choudhary V, Lakshmikanthan V, et al (2012). Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death. J Pharmacol Exp Ther, 341, 646-55.
  14. Koski A, Raki M, Nokisalmi P, et al (2012). Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther, 20, 221-9.
  15. Lebuffe G, Dosseh ED, Tek G, et al (2005). The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia, 60, 439-44.
  16. Lindberg G, Lindblad U, Low-Larsen B, et al (2002). Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study. Pharmacoepidemiol Drug Saf, 11, 493-7.
  17. Millward MJ, Cantwell BM, Munro NC, et al (1993). Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer, 67, 1031-5.
  18. Moore M, Manan A, Chow K, et al (2008). Cancer epidemiology and control in peninsular and island south-east asia - past, present and future. Asian Pac J Cancer Prev, 9, 81-98.
  19. Mross K, Bohn C, Edler L, et al (1993). Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. Ann Oncol, 4, 45-50.
  20. Nakai Y, Isayama H, Sasaki T, et al (2013). Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas, 42, 202-8.
  21. Ning Z, Chen D, Liu A, et al (2014). Efficacy of chemotherapy combined with targeted arterial infusion of verapamil in patients with advanced gastric cancer. Cell Biochem Biophys, 68, 195-200.
  22. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  23. Poch MA, Mehedint D, Green DJ, et al (2013). The association between calcium channel blocker use and prostate cancer outcome. Prostate, 73, 865-72.
  24. Salim E, Moore M, Al-Lawati J, et al (2009). Cancer epidemiology and control in the arab world - past, present and future. Asian Pac J Cancer Prev, 10, 3-10.
  25. Saltzman BS, Weiss NS, Sieh W, et al (2013). Use of antihypertensive medications and breast cancer risk. Cancer Causes Control, 24, 365-71.
  26. Sarfati D, Koczwara B, Jackson C (2016). The impact of comorbidity on cancer and its treatment. CA Cancer J Clin, 66, 337-50.
  27. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5.
  28. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 1-16.
  29. Vardar-Yagli N, Sener G, Saglam M, et al (2015). Associations among Physical Activity, Comorbidity, Functional Capacity, Peripheral Muscle Strength and Depression in Breast Cancer Survivors. Asian Pac J Cancer Prev, 16, 585-9.
  30. Williams GR, Mackenzie A, Magnuson A, et al (2015). Comorbidity in older adults with cancer. J Geriatr Oncol, 26725537.
  31. Wirasorn K, Suwanrungruag K, Wiangnon S, et al (2014). Numbers of new cases and trends of cancer 1993-2012: srinagarind hospital based population, Khon Kaen, North- East Thailand. Asian Pac J Cancer Prev, 15, 8423-7.
  32. Wong MC, Tam WW, Lao XQ, et al (2015). The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study. Int J Cardiol, 179, 178-85.
  33. Woodward M (2014). A Consensus Plan for Action to Improve Access to Cancer Care in the Association of Southeast Asian Nations (ASEAN) Region. Asian Pac J Cancer Prev, 15, 8521-6.
  34. Xuan Z, Zhong Z, Zhang X, et al (2012). Comorbidity Relationship to Outcome of Radical Cystectomy in Chinese: a Single Institution Study with the ACE-27 Comorbidity Index. Asian Pac J Cancer Prev, 13, 827-31.